Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma

Jacqueline Whang-Peng, Ann Lii Cheng, Chiun Hsu, Chien Ming Chen

研究成果: 雜誌貢獻回顧型文獻

23 引文 (Scopus)

摘要

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and about 600,000 patients suffer from HCC annually. The highest incidence is in Southeastern and Eastern Asia, with an incident rate of 18.3-35.5 per 100,000 population, and the lowest is in Central America with a rate of 2.1 per 100,000 population. HCC is one of the leading malignancies in Taiwan. Hepatitis B or C virus infections are the major factors for liver cancer in Taiwan. The survival time for patients with HCC without therapy after diagnosis averages 1-4 months. In this article, we review the risk factors, diagnostic criteria, staging systems, management and treatment of HCC. Treatments include liver transplantation, surgery, transcatheter arterial chemoembolization and transcatheter arterial embolization, percutaneous injection or radiofrequency ablation, chemotherapies, hormone therapy, internal radiation therapy, targeted therapy, a combination of chemotherapeutic agents and tyrosine kinase inhibitors, antiangiogenesis therapy, metabolic targets and Chinese herbal medicine. We propose three flow charts to guide surveillance, diagnosis, and treatment. Patients with high risk of HCC should be followed-up using the HCC High Risk Group Surveillance Flow Chart 1. If a mass is suspected, patients can be diagnosed using the HCC Diagnosis Flow Chart 2. On confirmation of HCC diagnosis, treatment should follow the HCC Treatment Flow Chart 3. Because the liver is the body's detoxification organ, its cells are already numerous with a high expression of the MDR gene. This makes chemotherapeutic drug treatment difficult. New molecular targeted therapy or new effective drugs are needed for difficult-to-treat HCC.
原文英語
頁(從 - 到)93-103
頁數11
期刊Journal of Experimental and Clinical Medicine
2
發行號3
DOIs
出版狀態已發佈 - 六月 2010

指紋

Hepatocellular Carcinoma
Therapeutics
Taiwan
Direction compound
Molecular Targeted Therapy
MDR Genes
Central America
Southeastern Asia
Far East
Herbal Medicine
Virus Diseases
Liver Neoplasms
Hepatitis B virus
Hepacivirus
Pharmaceutical Preparations
Liver Transplantation
Protein-Tyrosine Kinases
Population
Neoplasms
Radiotherapy

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. / Whang-Peng, Jacqueline; Cheng, Ann Lii; Hsu, Chiun; Chen, Chien Ming.

於: Journal of Experimental and Clinical Medicine, 卷 2, 編號 3, 06.2010, p. 93-103.

研究成果: 雜誌貢獻回顧型文獻

@article{c9e9a64ce2aa4049955f4144eb4a04de,
title = "Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and about 600,000 patients suffer from HCC annually. The highest incidence is in Southeastern and Eastern Asia, with an incident rate of 18.3-35.5 per 100,000 population, and the lowest is in Central America with a rate of 2.1 per 100,000 population. HCC is one of the leading malignancies in Taiwan. Hepatitis B or C virus infections are the major factors for liver cancer in Taiwan. The survival time for patients with HCC without therapy after diagnosis averages 1-4 months. In this article, we review the risk factors, diagnostic criteria, staging systems, management and treatment of HCC. Treatments include liver transplantation, surgery, transcatheter arterial chemoembolization and transcatheter arterial embolization, percutaneous injection or radiofrequency ablation, chemotherapies, hormone therapy, internal radiation therapy, targeted therapy, a combination of chemotherapeutic agents and tyrosine kinase inhibitors, antiangiogenesis therapy, metabolic targets and Chinese herbal medicine. We propose three flow charts to guide surveillance, diagnosis, and treatment. Patients with high risk of HCC should be followed-up using the HCC High Risk Group Surveillance Flow Chart 1. If a mass is suspected, patients can be diagnosed using the HCC Diagnosis Flow Chart 2. On confirmation of HCC diagnosis, treatment should follow the HCC Treatment Flow Chart 3. Because the liver is the body's detoxification organ, its cells are already numerous with a high expression of the MDR gene. This makes chemotherapeutic drug treatment difficult. New molecular targeted therapy or new effective drugs are needed for difficult-to-treat HCC.",
keywords = "Bevacizumab (Avastin), Chemoembolization (TACE), Erlotinib (Tarceva, OS1774), Gefitinib (Iressa), Hepatocellular carcinoma (HCC), Percutaneous injection, Radiofrequency ablation, Traditional Chinese medicine, Transcatheter arterial, Vascular endothelial growth factor (VEGF)",
author = "Jacqueline Whang-Peng and Cheng, {Ann Lii} and Chiun Hsu and Chen, {Chien Ming}",
year = "2010",
month = "6",
doi = "10.1016/S1878-3317(10)60016-2",
language = "English",
volume = "2",
pages = "93--103",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma

AU - Whang-Peng, Jacqueline

AU - Cheng, Ann Lii

AU - Hsu, Chiun

AU - Chen, Chien Ming

PY - 2010/6

Y1 - 2010/6

N2 - Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and about 600,000 patients suffer from HCC annually. The highest incidence is in Southeastern and Eastern Asia, with an incident rate of 18.3-35.5 per 100,000 population, and the lowest is in Central America with a rate of 2.1 per 100,000 population. HCC is one of the leading malignancies in Taiwan. Hepatitis B or C virus infections are the major factors for liver cancer in Taiwan. The survival time for patients with HCC without therapy after diagnosis averages 1-4 months. In this article, we review the risk factors, diagnostic criteria, staging systems, management and treatment of HCC. Treatments include liver transplantation, surgery, transcatheter arterial chemoembolization and transcatheter arterial embolization, percutaneous injection or radiofrequency ablation, chemotherapies, hormone therapy, internal radiation therapy, targeted therapy, a combination of chemotherapeutic agents and tyrosine kinase inhibitors, antiangiogenesis therapy, metabolic targets and Chinese herbal medicine. We propose three flow charts to guide surveillance, diagnosis, and treatment. Patients with high risk of HCC should be followed-up using the HCC High Risk Group Surveillance Flow Chart 1. If a mass is suspected, patients can be diagnosed using the HCC Diagnosis Flow Chart 2. On confirmation of HCC diagnosis, treatment should follow the HCC Treatment Flow Chart 3. Because the liver is the body's detoxification organ, its cells are already numerous with a high expression of the MDR gene. This makes chemotherapeutic drug treatment difficult. New molecular targeted therapy or new effective drugs are needed for difficult-to-treat HCC.

AB - Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and about 600,000 patients suffer from HCC annually. The highest incidence is in Southeastern and Eastern Asia, with an incident rate of 18.3-35.5 per 100,000 population, and the lowest is in Central America with a rate of 2.1 per 100,000 population. HCC is one of the leading malignancies in Taiwan. Hepatitis B or C virus infections are the major factors for liver cancer in Taiwan. The survival time for patients with HCC without therapy after diagnosis averages 1-4 months. In this article, we review the risk factors, diagnostic criteria, staging systems, management and treatment of HCC. Treatments include liver transplantation, surgery, transcatheter arterial chemoembolization and transcatheter arterial embolization, percutaneous injection or radiofrequency ablation, chemotherapies, hormone therapy, internal radiation therapy, targeted therapy, a combination of chemotherapeutic agents and tyrosine kinase inhibitors, antiangiogenesis therapy, metabolic targets and Chinese herbal medicine. We propose three flow charts to guide surveillance, diagnosis, and treatment. Patients with high risk of HCC should be followed-up using the HCC High Risk Group Surveillance Flow Chart 1. If a mass is suspected, patients can be diagnosed using the HCC Diagnosis Flow Chart 2. On confirmation of HCC diagnosis, treatment should follow the HCC Treatment Flow Chart 3. Because the liver is the body's detoxification organ, its cells are already numerous with a high expression of the MDR gene. This makes chemotherapeutic drug treatment difficult. New molecular targeted therapy or new effective drugs are needed for difficult-to-treat HCC.

KW - Bevacizumab (Avastin)

KW - Chemoembolization (TACE)

KW - Erlotinib (Tarceva, OS1774)

KW - Gefitinib (Iressa)

KW - Hepatocellular carcinoma (HCC)

KW - Percutaneous injection

KW - Radiofrequency ablation

KW - Traditional Chinese medicine

KW - Transcatheter arterial

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=77953894340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953894340&partnerID=8YFLogxK

U2 - 10.1016/S1878-3317(10)60016-2

DO - 10.1016/S1878-3317(10)60016-2

M3 - Review article

AN - SCOPUS:77953894340

VL - 2

SP - 93

EP - 103

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 3

ER -